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LETTER TO THE EDITOR
Comment on Publications from OpT2mise Study
National Diabetes Committee of Republic of Macedonia: Tatjana Milenkovic, MD, PhD,
Mirjana Kocova, MD, PhD, Brankica Krstevska, MD, PhD, Gordana Pemovska, MD, PhD,
and Ivica Smokovski, MD, PHD
Dear Editor:
It is well known that the type 2 diabetes ‘‘pandemic’’is spreading relentlessly throughout the world, and the
Republic of Macedonia is certainly not an exception: ac-
cording to the latest International Diabetes Federation Atlas
data from 2015, the country is occupying the unpopular third
place in Europe in terms of diabetes comparative prevalence
(10.3%), with the vast majority of cases (approximately 98%)
diagnosed with type 2 diabetes.1 Many factors have con-
tributed to such a high prevalence of type 2 diabetes in the
country, including the considerable rise in caloric intake per
capita with no concurrent physical activity,2 very high
smoking prevalence,3 and the transition from a socialist to a
market economy with jobs and income insecurity—leading to
steep rise in unemployment and associated stress. Such an
explosion of type 2 diabetes has been among the main reasons
for categorization of the Republic of Macedonia as a very
high-risk country in Europe in terms of cardiovascular
mortality.4 Consequently, type 2 diabetes prevalence in the
country and worldwide has been associated with alarming
socioeconomic effects: approximately 40% of the country’s
total budget for all reimbursed nonhospital medications was
spent only on insulin, glucometers, test strips, glucagon, insulin
needles, insulin pumps, and related supplies, provided free
through a government program, not including oral antidiabetes
drugs or other direct and indirect diabetes-related costs.5,6
The recently adopted Law on Healthcare Amendment
addresses diabetes mellitus as a specific medical condition
posing a serious threat to the whole society.7 In addition,
international guidelines were adopted as national diabetes
guidelines and were published in the Official Journal of the
country, where typically laws and by-laws are published.8
The Law on Healthcare Amendment also stipulated forma-
tion of the National Diabetes Committee, responsible for the
national diabetes care policy and strategy as well as for en-
suring adherence to the national diabetes guidelines by var-
ious stakeholders, including the evaluation of electronic
healthcare records.7
According to the national diabetes guidelines, treatment
with insulin pumps (continuous subcutaneous insulin infu-
sion [CSII]) is not recommended in type 2 diabetes patients in
the Republic of Macedonia, and insulin pumps and related
supplies provided free of charge through the Government
Program are aimed exclusively for type 1 diabetes patients, as
has been recommended and applied elsewhere.8,9
The University Clinic of Endocrinology, Diabetes and
Metabolic Disorders from the Republic of Macedonia was
one of the European centers participating in the OpT2mise
clinical study—a multicenter, international, randomized,
controlled, parallel-group study to evaluate the comparative
efficacy and safety of CSII and multiple daily injection
regimens in insulin-using patients with type 2 diabetes who
were suboptimally controlled with advanced basal–bolus
therapy.10–13
After the patients treated with CSII in the Republic of
Macedonia were evaluated, the National Diabetes Committee
was officially informed by the University Clinic of En-
docrinology, Diabetes and Metabolic Disorders that at least
13 type 2 diabetes patients were treated with insulin pumps
and supplies through the government program, after com-
pleting their participation in a clinical study with CSII in type
2 diabetes patients.10–13 Once their treatment was reviewed,
the National Diabetes Committee decided that those patients
should no longer be treated with CSII in accordance with the
national diabetes guidelines and should be switched to insulin
pen therapy instead.
After this decision, several of the affected patients directly
approached the National Diabetes Committee confirming that
they had participated in the clinical study with CSII; how-
ever, they claimed they had never been diagnosed with type 2
diabetes, but rather with type 1 diabetes.
National Diabetes Committee thoroughly examined the
electronic health records of all 13 patients from the National
eHealth System and found that all 13 of them had a record of
type 1 diabetes diagnosis during the study duration, despite
the fact that the clinical study inclusion criteria, both at
screening and at randomization, were limited to patients di-
agnosed with type 2 diabetes mellitus, as per the investiga-
tor’s discretion. Some of those patients were found to also
have a record of type 2 diabetes diagnosis, mainly after study
completion; however, at least three patients had a record of
only type 1 diabetes in the National eHealth System even
after study completion, up to the date of review (January 15,
2016).
The responsible physician acting as national Principal In-
vestigator in the mentioned study was asked by the National
Diabetes Committee for an explanation of these findings in
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numerous occasions; however, no reasonable explanation
was received.
It is our concern that such findings might have an impact
on the study results and conclusions as presented in the re-
cent publications, given the portion of patients enrolled from
the Republic of Macedonia out of the total number of re-
ported patients randomized on CSII (n = 168).10–13 Taking
into consideration the differences in the pathogenesis be-
tween type 1 and type 2 diabetes, as well as in the use of pump
therapy and overall management as recognized by the study
authors,10–13 we believe that inappropriate inclusion of type 1
diabetes patients in the clinical study with CSII in type 2
diabetes patients is a violation of inclusion criteria, might
affect the hypothesis of studying CSII in the largest homo-
geneous cohort of type 2 diabetes patients, and might distort
the study results and lead to misrepresenting conclusions.
These patients should be reevaluated by the international
Principal Investigator for the whole international study in
order to check and confirm the published results in several
studies published in journals with significant impact factor.
The National Diabetes Committee firmly believes that
newer treatments are essential for achieving improved gly-
cemic control in type 2 diabetes patients and strongly en-
courages clinical research in this area through multinational,
multicenter, randomized, controlled clinical studies. We al-
ready are experiencing numerous advanced treatments for
type 2 diabetes patients and are expecting even more to be
available, including the method of CSII as a viable option for
type 2 diabetes patients. However, we believe that these data
should be based on sound scientific evidence and should
certainly not be based on incorrect patient recruitment.
Our role to protect the health and well-being of diabetes
patients from the Republic of Macedonia, including type 2
diabetes patients, as well as the healthcare resources required
for sustainable diabetes care, necessitates that we also con-
tribute toward providing scientifically sound clinical data for
the benefit of all type 2 diabetes patients in Republic of
Macedonia, and throughout the world. Additionally, we en-
courage strict adherence to the highest standards of Good
Clinical Practice in international, multicenter clinical studies
to ensure generation of credible and verifiable clinical data
that might impact the recommendations in diabetes clinical
guidelines worldwide.
Therefore, we believe that our concerns relevant for the
patients enrolled in the clinical study from the Republic of
Macedonia should strongly be considered while interpreting
the OpT2mise clinical study’s results and conclusions. We
remain open and available for any additional requests or
queries that might arise.
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